查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1946344

結膜炎治療市場－全球產業規模、佔有率、趨勢、機會及預測（依疾病類型、製劑類型、地區及競爭格局分類，2021-2031年）

Conjunctivitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Formulation Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球結膜炎治療市場預計將從 2025 年的 58.7 億美元成長到 2031 年的 79.4 億美元，複合年成長率為 5.16%。

該市場涵蓋多種藥物製劑，包括抗病毒藥物、抗生素、抗組織胺藥物和肥大細胞穩定劑，旨在控制感染疾病和減輕結膜發炎。病毒性和過敏性結膜炎在全球發病率的上升是推動市場成長的主要因素，而過敏原暴露增加和環境污染往往會加劇病情。此外，人們對眼部健康的日益重視以及隱形眼鏡的廣泛使用也是推動市場成長的因素。根據小兒科感染疾病學會2024年報告，每年約有八分之一的兒童患有感染疾病結膜炎，這為該市場提供了巨大的需求基礎。

市場概覽
預測期 2027-2031
市場規模：2025年 58.7億美元
市場規模：2031年 79.4億美元
複合年成長率：2026-2031年 5.16%
成長最快的細分市場 過敏性結膜炎
最大的市場 北美洲

儘管成長指標積極，但由於重磅藥物專利到期以及非專利藥競爭加劇，市場仍面臨許多挑戰。這些低成本學名藥的進入給現有製藥公司的價格和利潤率帶來了巨大的下行壓力，可能抑制其對新藥研發的投資。因此，這種競爭環境會削弱品牌藥的盈利，並使市場充斥著同質化的治療方案，從而對市場擴張構成挑戰。

市場促進因素

全球感染疾病和過敏性結膜炎盛行率的不斷上升是推動治療市場成長的主要因素，從而對各種治療方法產生了穩定的需求。頻繁的季節性流行以及成年人群中慢性過敏性疾病負擔的加重進一步加劇了這一趨勢。例如，根據《印度斯坦時報》報道，2025年6月，孟買醫院由季節性病毒引起的結膜炎病例激增20-30%，凸顯了感染潮帶來的快速傳播和突發性需求激增。此外，非傳染性疾病也在擴大市場範圍。美國國立衛生研究院2025年7月引用的一項研究表明，英國約有八分之一的成年人患有過敏性鼻結膜炎，這意味著龐大的患者群體需要在兒童以外的長期管理。

同時，大量新型療法的核准和上市正在重塑市場格局，為患者提供更先進、更便利的治療選擇。製藥公司積極響應這項需求，推出現有藥物藥物的創新配方和經濟實惠的學名藥。在這一競爭格局中，Glenmark Pharmaceuticals公司於2025年3月獲得FDA核准的0.2%鹽酸奧洛他定滴眼液（USP）上市（根據Barchart數據），成為一項關鍵進展，擴大了有效治療眼癢的途徑。持續湧現的核准療法不僅有助於改善患者的用藥途徑，還能根據結膜炎的嚴重程度提供個人化解決方案，進而提升市場價值。

市場挑戰

重磅藥物專利到期以及隨之而來的非專利競爭，對全球結膜炎治療藥物市場的財務擴張構成了重大障礙。當專利配方失去獨佔權後，市場上充斥著大量價格較低的學名藥，導致價格大幅下降。這種轉變使成熟的治療方法商品化，即使處方量保持穩定甚至成長，也會導致製藥開發商的收入急劇下降。由於專利到期藥物導致的利潤率降低，限制了可用於研發再投資的資金，延緩了能夠推動未來市場價值成長的創新高價值治療方案的推出。

處方量與產生收入之間的脫節鮮明地體現了這種價值侵蝕。根據美國可及藥品協會（Association for Accessible Medicines）預測，到2025年，學名藥將占美國處方箋的90%，但僅佔藥品總支出的12%。這項數據表明，儘管患者用藥量依然很高，但由於低成本學名藥佔據市場主導地位，市場所獲得的貨幣價值卻不成比例地低。這種扭曲的財務狀況抑制了整體市場成長，因為高收入的品牌藥銷售被低利潤的學名藥銷售所取代，最終導致相關人員不願在眼科藥物輸送技術領域投入高成本的研發。

市場趨勢

遠距眼科的整合正在革新病患分診流程，尤其是在傳染性病毒疾病方面。透過遠端評估，臨床醫生無需進行身體接觸即可有效區分過敏性和感染性病因，從而顯著降低擁擠的臨床環境中的感染風險。這種方法已被廣泛採用，成為眼表疾病的主要篩檢工具。根據2025年1月發表在《醫師週刊》（Physicians Weekly）上的報導《遠距眼科作為急性眼疾的有效分診工具》，一項對6000多名患者的回顧性研究發現，所有遠端醫療就診中有15.5%是針對結膜疾病的，這凸結了遠距會診在急性病情就診中的重要性。

同時，奈米技術在眼科治療的應用正在解決傳統眼藥水生物利用度低這一重大難題。新型奈米載體，例如奈米混懸液，正在被開發用於提高皮質類固醇的溶解度和組織滲透性，這對於治療嚴重的發炎性結膜炎至關重要。與傳統製劑相比，這些先進的遞送系統能夠確保快速起效並維持療效。例如，根據2025年2月《現代驗光》雜誌上題為“2024年回顧：FDA核准和產品上市”的報導，一種新型水性懸浮液——0.05%Clobetasol Propionate索懸浮液——在四天內使80%的患者疼痛完全緩解，凸顯了基於奈米技術的製劑在治療眼部炎症方面的卓越療效。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球結膜炎治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依疾病類型（過敏性結膜炎、細菌性結膜炎、病毒性結膜炎）
    • 依劑型類型（軟膏、眼藥水、口服藥物）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美結膜炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲結膜炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區結膜炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲結膜炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲結膜炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球結膜炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Bausch & Lomb Inc
  • Allergan UnLtd Co
  • Nicox SA
  • Alembic Pharmaceuticals Ltd
  • Sanofi SA
  • Pfizer Inc
  • Sirion Therapeutics Inc
  • SANTEN PHARMACEUTICAL CO., LTD.
  • Auven Therapeutics Management LLLP

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19544

The Global Conjunctivitis Treatment Market is projected to expand from a valuation of USD 5.87 Billion in 2025 to USD 7.94 Billion by 2031, reflecting a CAGR of 5.16%. This market sector encompasses a broad spectrum of pharmaceutical formulations, such as antivirals, antibiotics, antihistamines, and mast cell stabilizers, all aimed at managing infection and reducing conjunctival inflammation. Market growth is fundamentally underpinned by the escalating global incidence of viral and allergic conjunctivitis, a trend exacerbated by rising allergen exposure and environmental pollution. Additionally, the market is bolstered by increased awareness of ocular health and the widespread use of contact lenses. Highlighting the significant demand from the pediatric demographic, the Pediatric Infectious Diseases Society reported in 2024 that infectious conjunctivitis affects approximately one in eight children annually, sustaining substantial market activity.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.87 Billion
Market Size 2031USD 7.94 Billion
CAGR 2026-20315.16%
Fastest Growing SegmentAllergic Conjunctivitis
Largest MarketNorth America

Despite these positive growth indicators, the market confronts a major obstacle due to the expiration of patents for key blockbuster drugs, leading to intensified competition from generic manufacturers. The entry of these lower-cost generic alternatives exerts significant downward pressure on pricing and revenue margins for established pharmaceutical companies, which may potentially hinder investment in novel drug development. Consequently, this competitive environment challenges market expansion by eroding the profitability of branded therapeutics and saturating the sector with commoditized treatment options.

Market Driver

The increasing global prevalence of infectious and allergic conjunctivitis serves as a primary catalyst for the growth of the treatment market, generating consistent demand for a variety of therapeutic interventions. This driver is fueled by frequent seasonal outbreaks and a rising burden of chronic allergic conditions among adult populations. For instance, the Hindustan Times reported that in June 2025, medical facilities in Mumbai observed a sharp 20% to 30% increase in conjunctivitis cases attributed to seasonal viral pathogens, underscoring the rapid transmissibility and acute demand associated with infectious waves. The market's scope is further broadened by non-infectious conditions; a study cited by the National Institutes of Health in July 2025 indicated that allergic rhinoconjunctivitis affects roughly one in eight adults in the UK, demonstrating a vast patient base requiring long-term management beyond the pediatric sector.

Simultaneously, the market is being reshaped by a surge in approvals and launches of novel therapeutic products, offering patients more advanced and accessible treatment choices. Pharmaceutical companies are actively responding to this demand by introducing both innovative formulations and cost-effective generic alternatives to existing drugs. A significant development in this competitive landscape occurred in March 2025 when, according to Barchart, Glenmark Pharmaceuticals received FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, thereby expanding access to effective treatments for ocular itching. This continuous influx of approved therapies not only improves patient access but also drives market value by providing tailored solutions for varying severities of conjunctival inflammation.

Market Challenge

The expiration of patents for blockbuster drugs and the subsequent rise of generic competition constitute a formidable barrier to the financial expansion of the global conjunctivitis treatment market. As exclusive rights to proprietary formulations lapse, the market sees an influx of low-cost generic alternatives that force prices down significantly. This transition commoditizes established treatments, causing a sharp decline in revenue for pharmaceutical developers despite consistent or even increasing prescription volumes. The reduced profit margins from these off-patent medications limit the capital available for reinvestment into research and development, thereby slowing the introduction of innovative, higher-value therapeutic solutions that could drive future market valuation.

The disparity between prescription volume and revenue generation clearly illustrates this value erosion. According to the Association for Accessible Medicines, in 2025, generic medicines accounted for 90% of prescriptions filled in the United States but represented only 12% of total drug spending. This data indicates that while patient usage remains high, the monetary value captured by the market is disproportionately low due to the dominance of lower-priced generics. Such a skewed financial landscape hampers overall market growth by replacing high-revenue branded streams with low-margin commodity sales, ultimately discouraging stakeholders from pursuing costly advancements in ocular drug delivery.

Market Trends

The integration of Tele-Ophthalmology for Remote Management is fundamentally transforming patient triage protocols, particularly for contagious viral forms of the condition. By facilitating remote assessment, clinicians can effectively distinguish between allergic and infectious etiologies without physical contact, thereby significantly reducing the risk of transmission within crowded clinic settings. This modality is witnessing substantial uptake as a primary screening tool for ocular surface complaints. As reported by Physicians Weekly in January 2025, in the 'Tele-ophthalmology as an effective triaging tool for acute ophthalmic concerns' article, a retrospective study of over 6,000 patients revealed that 15.5% of all telehealth encounters were specifically for conjunctival disorders, underscoring the high reliance on virtual care for managing acute conjunctivitis.

Concurrently, the adoption of Nanotechnology in Ocular Therapeutics is addressing critical bioavailability challenges associated with conventional eye drops. Novel nanocarriers, such as nanosuspensions, are being engineered to enhance the solubility and tissue penetration of corticosteroids, which are essential for managing severe inflammatory conjunctivitis. These advanced delivery systems ensure rapid therapeutic onset and sustained efficacy compared to traditional formulations. For instance, according to Modern Optometry in February 2025, within the '2024 in Review: FDA Approvals and Product Launches' article, clobetasol propionate ophthalmic suspension 0.05%, a novel aqueous nanosuspension, demonstrated that 80% of patients experienced complete pain relief within four days, highlighting the superior efficacy of nanotechnology-enabled formulations in treating ocular inflammation.

Key Market Players

  • Novartis AG
  • Bausch & Lomb Inc
  • Allergan UnLtd Co
  • Nicox S.A.
  • Alembic Pharmaceuticals Ltd
  • Sanofi SA
  • Pfizer Inc
  • Sirion Therapeutics Inc
  • SANTEN PHARMACEUTICAL CO., LTD.
  • Auven Therapeutics Management LLLP

Report Scope

In this report, the Global Conjunctivitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Conjunctivitis Treatment Market, By Disease Type

  • Allergic Conjunctivitis
  • Bacterial Conjunctivitis
  • Viral Conjunctivitis

Conjunctivitis Treatment Market, By Formulation Type

  • Ointment
  • Drops
  • Drugs

Conjunctivitis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Conjunctivitis Treatment Market.

Available Customizations:

Global Conjunctivitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Conjunctivitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis)
    • 5.2.2. By Formulation Type (Ointment, Drops, Drugs)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Conjunctivitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Formulation Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Conjunctivitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Formulation Type
    • 6.3.2. Canada Conjunctivitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Formulation Type
    • 6.3.3. Mexico Conjunctivitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Formulation Type

7. Europe Conjunctivitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Formulation Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Conjunctivitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Formulation Type
    • 7.3.2. France Conjunctivitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Formulation Type
    • 7.3.3. United Kingdom Conjunctivitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Formulation Type
    • 7.3.4. Italy Conjunctivitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Formulation Type
    • 7.3.5. Spain Conjunctivitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Formulation Type

8. Asia Pacific Conjunctivitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Formulation Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Conjunctivitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Formulation Type
    • 8.3.2. India Conjunctivitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Formulation Type
    • 8.3.3. Japan Conjunctivitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Formulation Type
    • 8.3.4. South Korea Conjunctivitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Formulation Type
    • 8.3.5. Australia Conjunctivitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Formulation Type

9. Middle East & Africa Conjunctivitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Formulation Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Conjunctivitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Formulation Type
    • 9.3.2. UAE Conjunctivitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Formulation Type
    • 9.3.3. South Africa Conjunctivitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Formulation Type

10. South America Conjunctivitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Formulation Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Conjunctivitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Formulation Type
    • 10.3.2. Colombia Conjunctivitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Formulation Type
    • 10.3.3. Argentina Conjunctivitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Formulation Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Conjunctivitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bausch & Lomb Inc
  • 15.3. Allergan UnLtd Co
  • 15.4. Nicox S.A.
  • 15.5. Alembic Pharmaceuticals Ltd
  • 15.6. Sanofi SA
  • 15.7. Pfizer Inc
  • 15.8. Sirion Therapeutics Inc
  • 15.9. SANTEN PHARMACEUTICAL CO., LTD.
  • 15.10. Auven Therapeutics Management LLLP

16. Strategic Recommendations

17. About Us & Disclaimer